Malfunction and overexpression of the calcium channel TRPC1 have been found associated with skeletal and cardiac muscle dystrophy, hypertension-induced cardiac hypertrophy and heart failure. Moreover, TRPCs may also be involved in tumorigenesis and metastatic proliferation. Although a specific pharmacology for this putative therapeutic target is lacking, low-affinity inhibitors binding to TRPC1, such as 2-APB and SKF-96365, have been described.
University of Bern, Department of Physiology
|Niggli Ernst (PI)